TIM3 antibody (AA 22-202)
Quick Overview for TIM3 antibody (AA 22-202) (ABIN7872305)
Target
See all TIM3 (TIM 3) AntibodiesReactivity
Host
Clonality
Conjugate
Application
Clone
-
-
Binding Specificity
- AA 22-202
-
Purpose
- TIM3 Antibody / HAVCR2
-
Purification
- Protein G affinity chromatography
-
Immunogen
- A portion of amino acids 22-202 from the human protein was used as the immunogen for the TIM3 antibody.
-
Isotype
- IgG2c, kappa
-
-
-
-
Application Notes
- Optimal dilution of the TIM3 antibody should be determined by the researcher.
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 0.2 mg/mL
-
Buffer
- 0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced) and 0.05 % sodium azide
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Storage
- 4 °C,-20 °C
-
Storage Comment
- Store the TIM3 antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).
-
-
- TIM3 (TIM 3) (Hepatitis A Virus Cellular Receptor 2 (TIM 3))
-
Alternative Name
- TIM3
-
Background
- TIMs are type I transmembrane glycoproteins with one Ig-like V-type domain and a Ser/Thr-rich mucin stalk. TIM-3 is expressed on the surface of effector T cel tonsil, lymph node or spleen. In chronic inflammation, autoimmune disorders, and some cancers, TIM-3 is upregulated on several other hematopoietic cell types. The Ig domain of TIM-3 interacts with a ligand on resting but not activated Th1 and Th2 cells. The glycosylated Ig domain of TIM-3 binds cell-associated galectin-9. This induces TIM-3 Tyr phosphorylation and pro-apoptotic signaling. TIM-3 functions as a negative regulator of Th1 cell activity. Its blockade results in increased IFN-gamma production, Th1 cell proliferation and cytotoxicity, regulatory T cell development, and increases in macrophage and neutrophil infiltration into sites of inflammation.
-
UniProt
- Q8TDQ0
-
Pathways
- Regulation of Lipid Metabolism by PPARalpha, Cancer Immune Checkpoints
Target
-